Sept 15 (Reuters) - Japanese pharma company Takeda Pharmaceutical Co said on Wednesday the U.S. Food and Drug Administration has granted an accelerated approval to its drug, Exkivity, to treat a type of lung cancer. (Reporting by Dania Nadeem in Bengaluru; Editing by Shailesh Kuber)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,096 JPY | -0.41% | -0.92% | +1.04% |
05-16 | Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment | MT |
05-15 | Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.04% | 40.96B | |
+39.22% | 731B | |
+32.16% | 586B | |
-7.85% | 348B | |
+15.48% | 319B | |
-0.12% | 273B | |
+13.51% | 235B | |
+7.53% | 202B | |
-6.95% | 203B | |
-3.37% | 158B |
- Stock Market
- Equities
- 4502 Stock
- News Takeda Pharmaceutical Company Limited
- Takeda Pharmaceutical : U.S. FDA approves Takeda's lung cancer therapy